EGFR and lung cancer: Choi et al. utilized porcine lung dECM with patient-derived tumor cells, fibrotic lung fibroblasts, and endothelial cells to generate lung cancer organoids that retained oncogenic profiles and resistance to EGFR-targeted therapies under fibrotic conditions [149].